The Australian arthroplasty thromboprophylaxis survey

Area of Science:

• Orthopedic Surgery
• Thromboprophylaxis
• Venous Thromboembolism

Background:

• Significant variability exists in thromboprophylaxis practices following joint arthroplasty.
• Current practices among Australian orthopedic surgeons require updated assessment.

Purpose of the Study:

• To survey Australian orthopedic surgeons regarding their current thromboprophylaxis strategies for hip and knee arthroplasty.
• To identify patterns in the duration, methods, and rationale for thromboprophylaxis.

Main Methods:

• A questionnaire was distributed to 1082 Australian orthopedic surgeons.
• 593 surgeons (55% response rate) completed the survey on prophylaxis practices.

Main Results:

• 98% of surgeons utilize chemical thromboprophylaxis, predominantly low-molecular-weight heparin (84% hip, 79% knee).
• Surgeons using low-molecular-weight heparin were more influenced by litigation fears and protocols compared to personal reading.
• A significant majority expressed a desire for formal guidelines on thromboprophylaxis in arthroplasty.

Conclusions:

• Low-molecular-weight heparin is the dominant chemical agent for thromboprophylaxis in Australian arthroplasty surgery.
• Practice patterns suggest a reliance on guidelines and a concern for litigation, highlighting a need for standardized recommendations.